GW&K Investment Management LLC Trims Position in Halozyme Therapeutics, Inc. $HALO

GW&K Investment Management LLC lessened its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,254,648 shares of the biopharmaceutical company’s stock after selling 7,069 shares during the period. Halozyme Therapeutics accounts for about 0.7% of GW&K Investment Management LLC’s portfolio, making the stock its 24th largest position. GW&K Investment Management LLC owned 1.07% of Halozyme Therapeutics worth $84,439,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. Measured Wealth Private Client Group LLC increased its stake in Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 124 shares during the period. Larson Financial Group LLC increased its stake in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares during the period. Clearstead Advisors LLC increased its stake in Halozyme Therapeutics by 107.7% in the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 265 shares during the period. Harbour Investments Inc. increased its stake in Halozyme Therapeutics by 152.5% in the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 372 shares during the period. Finally, Wexford Capital LP purchased a new position in Halozyme Therapeutics during the 3rd quarter valued at about $70,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $69.07, for a total value of $690,700.00. Following the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $53,030,564.60. This trade represents a 1.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $66.21, for a total transaction of $107,591.25. Following the completion of the sale, the director owned 43,669 shares in the company, valued at $2,891,324.49. This represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 93,250 shares of company stock worth $6,299,746 over the last 90 days. Company insiders own 2.50% of the company’s stock.

Analysts Set New Price Targets

HALO has been the topic of a number of research reports. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Morgan Stanley cut their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. UBS Group reissued a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Finally, TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $81.60.

Halozyme Therapeutics Trading Up 1.1%

NASDAQ HALO opened at $71.48 on Wednesday. Halozyme Therapeutics, Inc. has a one year low of $51.06 and a one year high of $82.22. The company has a market capitalization of $8.48 billion, a price-to-earnings ratio of 25.71, a price-to-earnings-growth ratio of 0.29 and a beta of 0.88. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The company’s 50-day simple moving average is $67.14 and its two-hundred day simple moving average is $68.74.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. During the same period last year, the business earned $1.11 EPS. The company’s revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.